Background: Perinatal HIV transmission could occur via microtransfused maternal blood during delivery. If so, detecting maternal cells in umbilical cord blood should correlate with infection risk.
Introduction
In settings where maternal antiretroviral treatment is not used, about a quarter of infants born to HIVþ women blood. Of uninfected infants, 15-20% became infected perinatally, defined by being PCR-negative in cord blood but PCR-positive in the first tested blood sample taken 1-2 months after birth [1, 2] . Thus, about 70% of the infants who are diagnosed as infected by 1-2 months of age acquired HIVat or very near the time of birth. The route of perinatal transmission seems likely to be across the placenta. There is little support for infection in the birth canal [1, 3] , and breast feeding in the first weeks of life appears to contribute little to perinatal infection risk [4] .
One plausible mechanism for perinatal transmission is by transfer of HIV-infected maternal cells into the fetal circulation at or near the time of delivery. Several reports describe the detection of fetal DNA in the mother's circulation during pregnancy and this approach has been applied to detect genetic abnormalities in the fetus [5, 6] . Transplacental microtransfusions from the mother to the fetus have also been documented using hybridization [7] and by PCR testing of DNA extracted from cells obtained from fresh cord blood. The frequency was estimated to be one maternal cell per 1000 to 10 000 child cells in midtrimester fetuses [8] .
However, obtaining this level of sensitivity is challenging when the target DNA is not greatly different from an overwhelming background of quite similar DNA, such as when blood from first-degree relatives (i.e., mother and child pairs) is admixed. We report here a semiquantitative approach using DNA extracted from dried blood spots (DBS), in which levels below one added cell per 1000 cells were reliably detected. We further used this technique to examine DBS made from umbilical cord blood to examine whether finding maternal DNA sequences was associated with perinatally acquired HIV infection in the infant.
Methods

Patients and materials
During a clinical invention trial in Blantyre, Malawi in 1994, women delivering at Queen Elizabeth Central Hospital were enrolled in a study to determine rates of HIV transmission with and without vaginal cleansing with chlorhexidine, an antiseptic known to neutralize HIV. Details of the design and conduct of that study have been described elsewhere [1] . During this study, HIV infection in the mother was determined by testing cord blood for passively transmitted antibody against HIV. HIV infection in the infant was determined by PCR on DBS made from the umbilical cord blood or heel sticks at various ages. DBS were stored in individual sealed plastic envelopes in a cold room (48C) until testing in 2007. Laboratory methods for sample collection and HIV testing have been reported in previous publications [1, 9, 10] . Infants found to be uninfected postnatally were assumed to be HIV-negative at all earlier ages, including at delivery. We confirmed that cord blood samples from infants previously found to be HIV-negative were indeed negative, by retesting cord blood DBS for HIV, using a highly sensitive reverse transcription-PCR method to seek sequences specific to HIV [11] .
For the current study, we examined a subset of maternalinfant pairs from the 1994 intervention study [1] . The original study was approved both by the University of Malawi Medical School and the Government of Malawi as well as by the National Institutes of Health (USA). The current study was approved by the National Cancer Institute as exempt from further ethical review because it used only anonymous and unlinkable materials collected as part of previously approved study. Both case and control infants were vaginally delivered singleton term infants born to untreated HIV-infected women and all were breast-fed. Infants who were HIV PCR-positive in cord blood samples were considered infected in utero and excluded. Infants who were PCR-negative in cord blood samples were all PCR-tested between 4 and 8 weeks after delivery, using DNA extracted from DBS obtained by heel stick. Infants who were HIV PCR-positive at 4-8 weeks were considered to have been infected perinatally. By design, the intended ratio of cases to controls was 1 : 2, but in some mother-child pairs, no PCR target sequences suitable for distinguishing mother and child were identified.
Laboratory methods
Testing strategy
The laboratory method required identification of a target sequence that was present in the maternal DNA but not the infant's DNA (i.e., informative allele). We approached this problem using methods recently developed in our laboratory for the purpose of detecting persistent chimeric cells following blood transfusion [12, 13] . To identify prospective targets, we examined maternal and child sample pairs, seeking a strong PCR target present only in the mother's cells. Once a target was identified, the cord blood spot samples were extracted and sequencespecific PCR testing was performed to detect and quantify maternal cells. All testing of both the control panel and clinical specimens was performed on coded dried blood spot samples so that the status of patients was unknown to the laboratory.
DNA preparation for identification of informative alleles
The dried blood spot filter paper was cut along the circumference of each blood spot. Scissors were cleaned with bleach and alcohol after each individual cutting to ensure that the scissors would not cross contaminate the samples. Each dried blood spot, expected to represent about 50 ml of blood, was soaked in 240 ml of phosphate buffered saline (PBS), vortexed and incubated for overnight at room temperature. After overnight incubation, Corbett Robotics digest buffer (Sigma, St Louis, Missouri, USA) was added and incubated at 608C for 2 h. Both the liquid and the filter paper were carefully transferred to the Corbett extraction plate. DNA extraction using the Universal Liquid Sample Xtractor protocol was followed. The procedure was performed using the automated X-tractor Gene Nucleic Acid Extraction System (Corbett Robotics, Townsville, Queensland, Australia). The DNA was eluted in 150 ml of solution A, to which an additional 150 ml solution B was added [13] .
Sensitivity testing
To determine sensitivity, we used 10-fold serial dilutions of blood-in-blood admixtures made into DBS in 1998 and stored in the same freezers as the test samples. Four undiluted test samples were initially tested to find appropriate target sequences. The dilution series were then tested blindly to determine the lowest dilution at which the target sequence could be detected. In all results, the starting material was a unique DBS (i.e., not pooled DNA from a common extract). Initial trials using a quantitative DQ alpha assay [12] indicated that each spot extract yielded an average of 14 983 amplifiable sequences (SD: 5153) of amplifiable DNA. Individual DBS from each dilution level were extracted and tested four (two series) or six (two series) times to assess replication of the results. Results for each set of samples are presented as the number of replicates detected as positive for the added DNA alleles divided by the number of replicates tested at each dilution. Sensitivity was assessed by probit analysis, pooling replicate results from all series for robustness.
DNA typing of maternal and cord blood samples
Plates for PCR typing were prepared and frozen at À808C. The 24 Â 16 typing plate format consisted of 12 columns of insertion/deletion PCR assays and 12 columns of HLA-DR PCR assays. The 12 insertion/ deletion PCR assays were specific for insertion/deletion polymorphisms and the PCR conditions were described elsewhere [12, 13] . The 12 HLA-DR PCR assays targeted DR1, DR3, DR4, DR7, DR8, DR9, DR10, DR11, DR12, DR13, DR15, and DR16 and the PCR conditions were also described in the same publications [12, 13] . Five microliters of DNA were added to 10 ml of PCR mix. The Roche LightCycler 486 (Roche Diagnostics, Basel, Switzerland) was used to perform the DNA typing using PCR amplification.
DNA preparation for microchimerism detection
The DBS filter papers were cut as described above and soaked in 400 ml PBS overnight at room temperature. For extraction, a modified protocol using Qiagen DNA mini kit reagents (Valencia, California, USA) was performed by adding 400 ml of Qiagen buffer AL and 20 ml protease. The filter and solution was vortexed and protein digestion occurred at 608C for 30 min. Four hundred microliters of 200 proof ethanol was added and vortexed. Both the liquid and filter were carefully transferred to the Qiagen DNA column. Wash procedures, per manufacturer's protocol, were then followed. The DNA was eluted in 200 ml of nucleic acid free water, and dried at 1008C before the addition of 200 ml solutions A and B [13] . The preparation was vortexed to reconstitute the DNA.
Amplification for microchimerism
Maternal and infant blood samples were typed and compared to identify informative strong-signal alleles present in maternal blood but not in offspring blood. After identification of informative maternal alleles, the paired cord blood DBS was extracted and amplified for the informative allele. For each patient, we amplified six replicates per informative allele. Twenty-five microliters of DNA was added to 50 ml of PCR mix. Amplification conditions were as described previously [12, 13] .
Statistical analysis
The correlation between mother-infant HIV transmission and detection of microchimerism was assessed by exact odds ratios (OR) [14] without further adjustments, because controls were closely matched to cases, as described above. Analysis of CD4 cell count and maternal viral level could not be done because the information was not available.
Results
In the serial dilution blood-in-blood sensitivity studies (Table 1) Table 1 . Detection of donor-specific DNA sequences in 10-fold serial dilutions of whole blood prepared using four control blood samples (A added into B, B added into A, C added into D and D added into C). These dilution series were processed into dried blood spots and stored in parallel with clinical specimens from infected mothers and umbilical cord blood from exposed infants (see Methods). The target informative sequence (present in the added DNA but not the diluent DNA) sought in each set is given in brackets. Numbers indicate the number of replicates found positive (þ) for the informative target sequence/number tested at that dilution. 9500 infant sequences, indicating that we were likely to detect a sample as positive for microtransfusion if one to two maternal sequences were present in a blood volume containing 15 000 infant alleles, the average number of DNA copies extracted from a single DBS, based on DQ alpha testing.
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In the tested samples from the study population, 68 mother-child pairs had adequate samples in both mother and child, including 22 
Discussion
The frequency of finding maternal DNA in newborn blood has not been adequately studied, possibly because there are few applications for such knowledge. However, emerging interest is being generated by concern over graft-versus-host disease associated with placenta-derived hematopoietic stem cell transplantations [15, 16] . These studies have documented very low concentrations of maternal leukocytes in 20-50% of cord blood samples, the frequency of detection depending on the sensitivity of the assays used. The PCR methods we present detected 95% of test samples with a concentration of one target cell per 1000 background cells. At this concentration, the test samples would have had approximately 15 target sequences in 15 000 amplifiable sequences, the typical extract yield in study samples. Using probit analysis for all dilutions, the effective median detection level was one copy in 9500 genomes. Thus, we had a 50% chance of detecting a sample as positive if one or two sequences were present in the DBS extract. When samples had very low levels of target sequences, the probability that the tested extract contained even a single target sequence governed the likelihood that the samples would be detected as positive.
We applied this assay to examine the frequency and magnitude of mother-to-fetus leukocyte transfer, as measured by the presence of maternal DNA in cord blood, in the context of perinatal HIV transmission. Despite finding that maternal DNA was commonly detected in cord blood, we did not find that detection correlated with HIV infection risk either qualitatively (any versus none) or semiquantitatively (replicate level). Indeed, perinatal HIV infection appeared to be equally common when no microtransfused maternal cells were detected and when all replicates were positive. Even if free virus in maternal plasma were responsible for HIV infection, the volume of plasma microtransfused would be expected to be approximately proportional to the number of cells found.
It seems likely that HIV transmission occurring at delivery results from transplacental HIV transfer. In previous studies, we [1] and others [3] were unable to demonstrate HIV transmission during passage through the birth canal. As all infants in this study were breast-fed, some postnatal infection might have occurred by breast feeding during the first month. Infection via breast feeding no doubt can occur in the first weeks of life [17] [18] [19] [20] but appears to be uncommon. In South Africa, total infection rates at 6 weeks of age were similar in breast-fed only and exclusively bottle-fed infants [4] , indicating that infection via breast milk was not a major contributor to infection risk.
The current study was intended to determine if microtransfusion during labor might explain the high risk of HIV transmission during the first weeks of life.
Our study failed to support this hypothesis despite finding a high frequency of detectible maternal DNA in cord blood. However, Kwiek et al. [21] , working independently in Malawi, recently reported a correlation between maternal DNA in cord blood and perinatal HIV transmission risk. Their report was based on data from nine infected and 69 uninfected infants, but despite small numbers, they observed significant associations between levels of detected maternal DNA in umbilical cord blood and intrapartum HIV transmission (P ¼ 0.02), as well as a surprising possible association with in-utero transmission (13 infected infants, P ¼ 0.06).
Several reservations need to be considered in evaluating our results. Other factors could have affected our ability to find an association. Mothers who transmitted HIV infection to their infants were likely to have higher HIV levels than those who did not transmit infection [22, 23] but maternal HIV levels were not available in the current study. Likewise, although all infants were vaginally delivered, other delivery factors such as labor duration could have affected the results slightly. Furthermore, mothers who share more HLA concordance with their children are more likely to transmit HIV to their newborns [24, 25] . Testing for maternal DNA depleted our samples on these patients, precluding further genetic analyses to determine relative histocompatibility. However, we doubt that these small influences would have affected the outcome of this study.
Sample quality also needs to be considered. The sensitivity panel and test DBS samples were both prepared years ago (1998 and 1994, respectively) and stored similarly, so results in the sensitivity panel were likely to apply to tested samples. We appeared to have adequate samples, given the high frequency of detection we found. We could not determine how much blood might have entered the newborn because transfused maternal cells might have been introduced into the cord blood just prior to sampling and, thus, maternal cell concentration in cord blood could have been higher than in the systemic circulation of the infant. Finally, contamination of the cord blood sample by maternal blood could have occurred during collection. The collection procedures, described elsewhere [1] , were intended to be simple and straight forward as samples were obtained by midwives in an active obstetrical service in an African hospital. In a previous report [2] , using samples from this study, we assessed the frequency of HIV contamination by PCR-testing 48 cord blood samples from infants who had been born to HIV-infected women but were not infected with HIV. None was positive (upper 95% CI: 6%). However, PCR testing for HIV may not rule out a very low level of contamination by maternal cells as the majority of circulating lymphocytes would not be HIVinfected. Only a few hundred nucleated maternal cells contaminating the initial cord blood collection before the blood was spotted on Guthrie cards for storage would have resulted in maternal DNA levels at a level (one in 10 000) we might have detected as positive. Although the high level of sensitivity we achieved in the current study makes us concerned about detection of maternal cells contaminating the cord blood during initial specimen collection, we would still expect to have observed correlations with perinatal HIV infection rates if microtransfusion had been a major contributor to perinatal infection.
On the basis of the current study, the route by which infants become HIV-infected remains an enigma. Given the contrast between our findings and those of Kwiek et al. [21] , further work will be required. The approach and techniques described in this paper for detecting lowlevel chimerism should have many applications in other settings.
